{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:23:26Z","timestamp":1791944606808,"version":"4.3.4"},"reference-count":165,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Medicinska Fakulteten, Lunds Universitet, Sweden"},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["190157 Fk"],"award-info":[{"award-number":["190157 Fk"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271-TRR 205)"],"award-info":[{"award-number":["314061271-TRR 205)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with regard to clinical presentation, proliferative markers, clinical course, and response to therapy. Half of them show an aggressive course only many years after the first apparently benign presentation. APTs and PCs share several properties, but a Ki67 index greater than or equal to 10% and extensive p53 expression are more prevalent in PCs. Mutations in TP53 and ATRX are the most common genetic alterations; their detection might be of value for early identification of aggressiveness.<\/jats:p>\n                  <jats:p>Treatment requires a multimodal approach including surgery, radiotherapy, and drugs. Temozolomide is the recommended first-line chemotherapy, with response rates of about 40%. Immune checkpoint inhibitors have emerged as second-line treatment in PCs, with currently no evidence for a superior effect of dual therapy compared to monotherapy with PD-1 blockers. Bevacizumab has resulted in partial response (PR) in few patients; tyrosine kinase inhibitors and everolimus have generally not been useful. The effect of peptide receptor radionuclide therapy is limited as well.<\/jats:p>\n                  <jats:p>Management of APT\/PC is challenging and should be discussed within an expert team with consideration of clinical and pathological findings, age, and general condition of the patient. Considering that APT\/PCs are rare, new therapies should preferably be evaluated in shared standardized protocols. Prognostic and predictive markers to guide treatment decisions are needed and are the scope of ongoing research.<\/jats:p>","DOI":"10.1210\/clinem\/dgad098","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T10:51:27Z","timestamp":1677667887000},"page":"1585-1601","source":"Crossref","is-referenced-by-count":85,"title":["Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4844-8336","authenticated-orcid":false,"given":"Pia","family":"Burman","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Sk\u00e5ne University Hospital, Lund University , 205 02 Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivera","family":"Casar-Borota","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics, and Pathology; Uppsala University , 751 85 Uppsala , Sweden"},{"name":"Department of Clinical Pathology, Uppsala University Hospital , 751 85 Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Gustavo","family":"Perez-Rivas","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, Klinikum der Universit\u00e4t M\u00fcnchen, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , 80804 Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf M","family":"Dekkers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Section of Endocrinology & Clinical Epidemiology), Leiden University Medical Centre , 2333 ZA Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"issue":"2","key":"2023061601031611500_dgad098-B1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11154-020-09556-7","article-title":"The epidemiology of aggressive pituitary tumors (and its challenges)","volume":"21","author":"Dekkers","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"2023061601031611500_dgad098-B2","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"Clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2023061601031611500_dgad098-B3","author":"WHO Classification of Tumours Editorial Board"},{"issue":"1","key":"2023061601031611500_dgad098-B4","doi-asserted-by":"crossref","first-page":"D1","DOI":"10.1530\/EJE-19-0058","article-title":"Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas","volume":"181","author":"Chanson","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023061601031611500_dgad098-B5","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2016-4061","article-title":"Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: a study from two large UK centers","volume":"102","author":"Tampourlou","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023061601031611500_dgad098-B6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023061601031611500_dgad098-B7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2023061601031611500_dgad098-B8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2023061601031611500_dgad098-B9","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.ghir.2021.101430","article-title":"Growth hormone secreting pituitary carcinomas: case report and review of literature","volume":"60-61","author":"Vekaria","year":"2021","journal-title":"Growth Horm IGF Res"},{"issue":"6","key":"2023061601031611500_dgad098-B10","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1530\/EJE-14-0013","article-title":"The challenges in managing giant prolactinomas","volume":"170","author":"Maiter","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2023061601031611500_dgad098-B11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3","article-title":"Pituitary carcinoma. A clinicopathologic study of 15 cases","volume":"79","author":"Pernicone","year":"1997","journal-title":"Cancer"},{"issue":"3","key":"2023061601031611500_dgad098-B12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11060-015-1991-y","article-title":"Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas","volume":"126","author":"Losa","year":"2016","journal-title":"J Neurooncol"},{"issue":"5","key":"2023061601031611500_dgad098-B13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1530\/EJE-15-0189","article-title":"The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study","volume":"173","author":"Agustsson","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2023061601031611500_dgad098-B14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas. A review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"2023061601031611500_dgad098-B15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12022-015-9398-z","article-title":"The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas","volume":"26","author":"Nishioka","year":"2015","journal-title":"Endocr Pathol"},{"issue":"1","key":"2023061601031611500_dgad098-B16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1210\/jc.2009-1360","article-title":"Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation","volume":"95","author":"Lania","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023061601031611500_dgad098-B17","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1210\/jc.2014-4350","article-title":"Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide","volume":"100","author":"Bengtsson","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023061601031611500_dgad098-B18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1227\/01.neu.0000429858.96652.1e","article-title":"A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas","volume":"73","author":"Jahangiri","year":"2013","journal-title":"Neurosurgery"},{"issue":"2","key":"2023061601031611500_dgad098-B19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12020-016-1028-0","article-title":"The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1\/3","volume":"56","author":"Righi","year":"2017","journal-title":"Endocrine"},{"issue":"1","key":"2023061601031611500_dgad098-B20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11102-017-0844-4","article-title":"Predictors of silent corticotroph adenoma recurrence: a large retrospective single center study and systematic literature review","volume":"21","author":"Langlois","year":"2018","journal-title":"Pituitary"},{"issue":"7","key":"2023061601031611500_dgad098-B21","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1210\/jc.2018-00688","article-title":"Clinical and pathological aspects of silent pituitary adenomas","volume":"104","author":"Drummond","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023061601031611500_dgad098-B22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1385\/ENDO:28:1:115","article-title":"Pituitary carcinoma: diagnosis and treatment","volume":"28","author":"Lopes","year":"2005","journal-title":"Endocrine"},{"issue":"4","key":"2023061601031611500_dgad098-B23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1530\/EJE-18-0795","article-title":"Treatment and long-term outcomes in pituitary carcinoma: a cohort study","volume":"181","author":"Santos-Pinheiro","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023061601031611500_dgad098-B24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11102-017-0857-z","article-title":"Malignant transformation in non-functioning pituitary adenomas","volume":"21","author":"Lenders","year":"2018","journal-title":"Pituitary"},{"issue":"9","key":"2023061601031611500_dgad098-B25","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1210\/jc.2011-1166","article-title":"Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course\u2014case report and review of the literature","volume":"96","author":"Dudziak","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023061601031611500_dgad098-B26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s11102-018-0872-8","article-title":"Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review","volume":"21","author":"Yoo","year":"2018","journal-title":"Pituitary"},{"issue":"1","key":"2023061601031611500_dgad098-B27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11102-007-0080-4","article-title":"Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature","volume":"12","author":"van der Klaauw","year":"2009","journal-title":"Pituitary"},{"issue":"9","key":"2023061601031611500_dgad098-B28","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00259-016-3328-2","article-title":"Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET\/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle","volume":"43","author":"Nilica","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2023061601031611500_dgad098-B29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4103\/sni.sni_498_16","article-title":"Pituitary carcinoma: a case report and discussion of potential value of combined use of Ga-68 DOTATATE and F-18 FDG PET\/CT scan to better choose therapy","volume":"8","author":"Garmes","year":"2017","journal-title":"Surg Neurol Int"},{"issue":"12","key":"2023061601031611500_dgad098-B30","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/RLU.0000000000003804","article-title":"68Ga-DOTATATE PET\/CT in pituitary carcinoma","volume":"46","author":"Kaya","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"3","key":"2023061601031611500_dgad098-B31","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1097\/RLU.0000000000004029","article-title":"A rare case of pituitary carcinoma with bone metastases: 68Ga-DOTATATE PET\/CT findings","volume":"47","author":"Filizoglu","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"8","key":"2023061601031611500_dgad098-B32","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1210\/jc.2019-00012","article-title":"Pituitary metastases\u2014a nationwide study on the current characteristics with special reference to breast cancer","volume":"104","author":"Schill","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023061601031611500_dgad098-B33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11102-013-0542-9","article-title":"Clinical and biochemical characteristic features of metastatic cancer to the sella turcica: an analytical review","volume":"17","author":"Al-Aridi","year":"2014","journal-title":"Pituitary"},{"issue":"9","key":"2023061601031611500_dgad098-B34","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1097\/PAS.0000000000000908","article-title":"Serotonin, ATRX, and DAXX expression in pituitary adenomas: markers in the differential diagnosis of neuroendocrine tumors of the sellar region","volume":"41","author":"Casar-Borota","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2023061601031611500_dgad098-B35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/nan.12568","article-title":"Invited review: pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint","volume":"46","author":"Manojlovic-Gacic","year":"2020","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"2023061601031611500_dgad098-B36","first-page":"75","article-title":"Pituitary adenomas and craniopharyngiomas are CDX2 negative neoplasms","volume":"48","author":"Schittenhelm","year":"2010","journal-title":"Folia Neuropathol"},{"issue":"5","key":"2023061601031611500_dgad098-B37","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s11102-021-01178-9","article-title":"Pituitary metastases from neuroendocrine neoplasms: case report and narrative review","volume":"24","author":"Ragni","year":"2021","journal-title":"Pituitary"},{"key":"2023061601031611500_dgad098-B38","first-page":"14","volume-title":"World Health Organization Classification of Tumours of Endocrine Organs.","author":"Osamura","year":"2017","edition":"4th ed"},{"issue":"14","key":"2023061601031611500_dgad098-B39","doi-asserted-by":"crossref","first-page":"e6483","DOI":"10.1097\/MD.0000000000006483","article-title":"Progressive visual disturbance and enlarging prolactinoma caused by melanoma metastasis: a case report and literature review","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2023061601031611500_dgad098-B40","volume-title":"Pathology and Genetics of Tumours of Endocrine Organs.","author":"DeLellis","year":"2004"},{"issue":"2","key":"2023061601031611500_dgad098-B41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/eje.1.02326","article-title":"Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry","volume":"156","author":"Saeger","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2023061601031611500_dgad098-B42","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3171\/2016.12.JNS162126","article-title":"Atypical pituitary adenoma: a clinicopathologic case series","volume":"128","author":"Rutkowski","year":"2018","journal-title":"J Neurosurg"},{"issue":"2","key":"2023061601031611500_dgad098-B43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000375448","article-title":"Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis","volume":"101","author":"Chiloiro","year":"2015","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2023061601031611500_dgad098-B44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11154-020-09562-9","article-title":"Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions","volume":"21","author":"Trouillas","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"9","key":"2023061601031611500_dgad098-B45","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41379-022-01062-2","article-title":"P53 null phenotype is a \u201cpositive result\u201d in urothelial carcinoma in situ","volume":"35","author":"Sangoi","year":"2022","journal-title":"Mod Pathol"},{"issue":"4","key":"2023061601031611500_dgad098-B46","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/his.14726","article-title":"Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leaukemia","volume":"81","author":"Fitzpatrick","year":"2022","journal-title":"Histopathology"},{"issue":"9","key":"2023061601031611500_dgad098-B47","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/modpathol.2011.85","article-title":"Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis","volume":"24","author":"Yemelyanova","year":"2011","journal-title":"Mod Pathol"},{"issue":"11","key":"2023061601031611500_dgad098-B48","doi-asserted-by":"crossref","first-page":"e0187667","DOI":"10.1371\/journal.pone.0187667","article-title":"Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma","volume":"12","author":"Ali","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"2023061601031611500_dgad098-B49","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2265.2008.03404.x","article-title":"P53 gene mutation in an atypical corticotroph adenoma with Cushing's disease","volume":"70","author":"Kawashima","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2023061601031611500_dgad098-B50","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1227\/NEU.0b013e318217161a","article-title":"A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report","volume":"68","author":"Murakami","year":"2011","journal-title":"Neurosurgery"},{"issue":"4","key":"2023061601031611500_dgad098-B51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11102-009-0194-y","article-title":"Possible role of a radiation-induced p53 mutation in a Nelson's syndrome patient with a fatal outcome","volume":"14","author":"Pinto","year":"2011","journal-title":"Pituitary"},{"issue":"4","key":"2023061601031611500_dgad098-B52","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12022-007-9006-y","article-title":"P53 gene mutations in pituitary carcinomas","volume":"18","author":"Tanizaki","year":"2007","journal-title":"Endocr Pathol"},{"issue":"4","key":"2023061601031611500_dgad098-B53","doi-asserted-by":"crossref","first-page":"e1183","DOI":"10.1210\/clinem\/dgaa749","article-title":"Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations","volume":"106","author":"Casar-Borota","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023061601031611500_dgad098-B54","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/cen.14827","article-title":"Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients","volume":"97","author":"Guaraldi","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023061601031611500_dgad098-B55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s40478-022-01437-1","article-title":"TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome","volume":"10","author":"Perez-Rivas","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"2023061601031611500_dgad098-B56","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s12022-021-09693-y","article-title":"Two pituitary neuroendocrine tumors (PitNETs) with very high proliferation and TP53 mutation\u2014high-grade PitNET or PitNEC?","volume":"33","author":"Saeger","year":"2022","journal-title":"Endocr Pathol"},{"issue":"10","key":"2023061601031611500_dgad098-B57","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/neuonc\/noz109","article-title":"Driver mutations in USP8 wild-type Cushing's disease","volume":"21","author":"Sbiera","year":"2019","journal-title":"Neuro Oncol"},{"issue":"3","key":"2023061601031611500_dgad098-B58","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/clinem\/dgaa853","article-title":"USP8 And TP53 drivers are associated with CNV in a corticotroph adenoma cohort enriched for aggressive tumors","volume":"106","author":"Uzilov","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2023061601031611500_dgad098-B59","article-title":"Data from \u201cIntegrative genomic analysis of a corticotroph adenoma cohort enriched for aggressive and atypical tumors reveals an association of copy number variant landscape with USP8 and TP53 driver status","author":"Uzilov","year":"2020","journal-title":"Dryad"},{"key":"2023061601031611500_dgad098-B60","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3389\/fonc.2018.00510","article-title":"Identification of novel genes involved in the pathogenesis of an ACTH-secreting pituitary carcinoma: a case report and literature review","volume":"8","author":"Guo","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"2023061601031611500_dgad098-B61","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12020-021-02954-0","article-title":"ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations. Case report and review of the literature","volume":"76","author":"Sumislawski","year":"2022","journal-title":"Endocrine"},{"issue":"1","key":"2023061601031611500_dgad098-B62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ng.3166","article-title":"Mutations in the deubiquitinase gene USP8 cause Cushing's disease","volume":"47","author":"Reincke","year":"2015","journal-title":"Nat Genet"},{"issue":"3","key":"2023061601031611500_dgad098-B63","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/cr.2015.20","article-title":"Recurrent gain-of-function USP8 mutations in Cushing's disease","volume":"25","author":"Ma","year":"2015","journal-title":"Cell Res"},{"issue":"7","key":"2023061601031611500_dgad098-B64","doi-asserted-by":"crossref","first-page":"E997","DOI":"10.1210\/jc.2015-1453","article-title":"The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing's disease","volume":"100","author":"P\u00e9rez-Rivas","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023061601031611500_dgad098-B65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"issue":"8","key":"2023061601031611500_dgad098-B66","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/ERC-22-0088","article-title":"Improved pasireotide response in USP8 mutant corticotroph tumours in vitro","volume":"29","author":"Albani","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2023061601031611500_dgad098-B67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/EJE-15-0689","article-title":"The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease","volume":"174","author":"Hayashi","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023061601031611500_dgad098-B68","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12020-018-1776-0","article-title":"Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas","volume":"63","author":"Losa","year":"2019","journal-title":"Endocrine"},{"issue":"9","key":"2023061601031611500_dgad098-B69","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.3390\/ijms23094861","article-title":"The genomic landscape of corticotroph tumors: from silent adenomas to ACTH-secreting carcinomas","volume":"23","author":"Andonegui-Elguera","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2023061601031611500_dgad098-B70","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/s41467-020-16052-8","article-title":"Somatic SF3B1 hotspot mutation in prolactinomas","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"2023061601031611500_dgad098-B71","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/jpm10030088","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature","volume":"10","author":"Duhamel","year":"2020","journal-title":"J Pers Med"},{"key":"2023061601031611500_dgad098-B72","author":"Burman","year":"2023"},{"issue":"1","key":"2023061601031611500_dgad098-B73","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40478-020-01067-5","article-title":"Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis","volume":"8","author":"Lasolle","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"2023061601031611500_dgad098-B74","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1210\/jc.2018-02164","article-title":"Large genomic aberrations in corticotropinomas are associated with greater aggressiveness","volume":"104","author":"Tatsi","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023061601031611500_dgad098-B75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2265.2004.02046.x","article-title":"Prediction of recurrence of nonfunctioning pituitary tumours by loss of heterozygosity analysis","volume":"61","author":"Buch","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023061601031611500_dgad098-B76","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1750-3639.2011.00476.x","article-title":"Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors","volume":"21","author":"Wierinckx","year":"2011","journal-title":"Brain Pathol"},{"issue":"1","key":"2023061601031611500_dgad098-B77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-017-2530-9","article-title":"Ischemic stroke after irradiation for pituitary adenomas, a systematic review","volume":"135","author":"van Westrhenen","year":"2017","journal-title":"Neurooncol"},{"issue":"3","key":"2023061601031611500_dgad098-B78","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1210\/jc.2016-3402","article-title":"Radiotherapy, especially at young age, increases the risk for de novo brain tumors in patients treated for pituitary\/sellar lesions","volume":"102","author":"Burman","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2023061601031611500_dgad098-B79","first-page":"43","article-title":"Stereotactic radiosurgery for pituitary carcinoma","author":"Mehta","year":"2021","journal-title":"Gamma Knife Neurosurgery in the Management of Intracranial Disorders II"},{"issue":"3","key":"2023061601031611500_dgad098-B80","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-20-1088","article-title":"Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations","volume":"184","author":"Reincke","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023061601031611500_dgad098-B81","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr Mol Pharmacol"},{"issue":"4","key":"2023061601031611500_dgad098-B82","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.phrs.2007.08.003","article-title":"Triazene compounds: mechanism of action and related DNA repair systems","volume":"56","author":"Marchesi","year":"2007","journal-title":"Pharmacol Res"},{"issue":"4","key":"2023061601031611500_dgad098-B83","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3171\/jns.2006.105.4.621","article-title":"Long-term response of pituitary carcinoma to temozolomide. Report of two cases","volume":"105","author":"Fadul","year":"2006","journal-title":"J Neurosurg"},{"issue":"4","key":"2023061601031611500_dgad098-B84","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2265.2006.02653.x","article-title":"Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm","volume":"65","author":"Syro","year":"2006","journal-title":"Clin Endocrinol"},{"issue":"6","key":"2023061601031611500_dgad098-B85","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(06)70728-8","article-title":"Temozolomide: a novel treatment for pituitary carcinoma","volume":"7","author":"Lim","year":"2006","journal-title":"Lancet Oncol"},{"issue":"10","key":"2023061601031611500_dgad098-B86","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1210\/jc.2010-0644","article-title":"Temozolomide treatment in aggressive pituitary tumours and pituitary carcinomas: a French multicenter experience","volume":"95","author":"Raverot","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023061601031611500_dgad098-B87","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1210\/jc.2012-2924","article-title":"DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumours","volume":"98","author":"Hirohata","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2023061601031611500_dgad098-B88","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.wneu.2018.07.082","article-title":"Early recognition and initiation of temozolomide chemotherapy for refractory, invasive pituitary macroprolactinoma with long-term sustained remission","volume":"118","author":"Barkhoudarian","year":"2018","journal-title":"World Neurosurg"},{"issue":"3","key":"2023061601031611500_dgad098-B89","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12020-018-1751-9","article-title":"Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide","volume":"62","author":"Bengtsson","year":"2018","journal-title":"Endocrine"},{"issue":"10","key":"2023061601031611500_dgad098-B90","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/neuonc\/now059","article-title":"Is there a role for early chemotherapy in the management of pituitary adenomas?","volume":"18","author":"Lin","year":"2016","journal-title":"Neuro Oncol"},{"issue":"9","key":"2023061601031611500_dgad098-B91","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1530\/ERC-19-0083","article-title":"How and when to use temozolomide to treat aggressive pituitary tumours","volume":"26","author":"Whitelaw","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2023061601031611500_dgad098-B92","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11154-020-09551-y","article-title":"Temozolomide therapy for aggressive pituitary tumours\u2014current understanding and future perspective","volume":"21","author":"Burman","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"2023061601031611500_dgad098-B93","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/0284186X.2018.1557786","article-title":"Long-term cognitive dysfunction after radiation therapy for primary brain tumors","volume":"58","author":"Haldbo-Classen","year":"2019","journal-title":"Acta Oncol"},{"issue":"10","key":"2023061601031611500_dgad098-B94","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/0284186X.2019.1629014","article-title":"Radiation doses to brain substructures associated with cognition in radiotherapy of pediatric brain tumors","volume":"58","author":"Toussaint","year":"2019","journal-title":"Acta Oncol"},{"issue":"10","key":"2023061601031611500_dgad098-B95","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2023061601031611500_dgad098-B96","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"32","key":"2023061601031611500_dgad098-B97","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol"},{"issue":"18","key":"2023061601031611500_dgad098-B98","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1002\/cncr.27441","article-title":"O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide","volume":"118","author":"Lechapt-Zalcman","year":"2012","journal-title":"Cancer"},{"issue":"10","key":"2023061601031611500_dgad098-B99","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1365-2362.2011.02520.x","article-title":"Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status","volume":"41","author":"McCormack","year":"2011","journal-title":"Eur J Clin Investig"},{"issue":"3","key":"2023061601031611500_dgad098-B100","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11060-011-0532-6","article-title":"MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas","volume":"104","author":"Salehi","year":"2011","journal-title":"J Neurooncol"},{"issue":"4","key":"2023061601031611500_dgad098-B101","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1750-3639.2008.00153.x","article-title":"Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker","volume":"18","author":"Preusser","year":"2008","journal-title":"Brain Pathol"},{"issue":"2","key":"2023061601031611500_dgad098-B102","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00401-007-0279-5","article-title":"MGMT immunoexpression predicts responsiveness of pituitary tumours to temozolomide therapy","volume":"115","author":"Kovacs","year":"2008","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2023061601031611500_dgad098-B103","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-09-0389","article-title":"Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy","volume":"161","author":"Hagen","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023061601031611500_dgad098-B104","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1365-2265.2012.04373.x","article-title":"Temozolomide in the management of dopamine agonist-resistant prolactinomas","volume":"76","author":"Whitelaw","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2023061601031611500_dgad098-B105","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11102-011-0363-7","article-title":"Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature","volume":"15","author":"Annamalai","year":"2012","journal-title":"Pituitary"},{"issue":"3","key":"2023061601031611500_dgad098-B106","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1210\/jc.2017-02332","article-title":"Reduced expression of mismatch repair genes MSH6\/MSH2 directly promotes pituitary tumor growth via the ATR-Chk1 pathway","volume":"103","author":"Uraki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"8-9","key":"2023061601031611500_dgad098-B107","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.dnarep.2004.06.006","article-title":"Mismatch repair and DNA damage signaling","volume":"3","author":"Stojic","year":"2004","journal-title":"DNA Repair (Amst)"},{"issue":"18","key":"2023061601031611500_dgad098-B108","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/1078-0432.CCR-13-1856","article-title":"Novel MSH6 mutations in treatment-na\u00efve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation","volume":"20","author":"Nguyen","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023061601031611500_dgad098-B109","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/1078155215569556","article-title":"Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: hormonal and radiographic response","volume":"22","author":"Strowd","year":"2016","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"2023061601031611500_dgad098-B110","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11102-015-0694-x","article-title":"Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment","volume":"19","author":"Campder\u00e1","year":"2016","journal-title":"Pituitary"},{"key":"2023061601031611500_dgad098-B111","first-page":"18-0092","article-title":"Effective long-term temozolomide rechallenge in a macroprolactinoma","volume":"2018","author":"Zampetti","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"3","key":"2023061601031611500_dgad098-B112","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1158\/1078-0432.CCR-07-1856","article-title":"In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide","volume":"14","author":"Kil","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023061601031611500_dgad098-B113","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijrobp.2009.04.026","article-title":"Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts","volume":"75","author":"Carlson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2023061601031611500_dgad098-B114","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11060-020-03579-5","article-title":"Stereotactic reirradiation with etmozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas","volume":"149","author":"Minniti","year":"2020","journal-title":"J Neurooncol"},{"key":"2023061601031611500_dgad098-B115","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1200\/jco.2005.23.16_suppl.4216","article-title":"Effective treatment of neuroendocrine tumors with temozolomide and capecitabine","volume":"23","author":"Fine","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023061601031611500_dgad098-B116","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12022-019-9568-5","article-title":"An institutional experience of tumor progression to pituitary carcinoma in a 15-year cohort of 1055 consecutive pituitary neuroendocrine tumors","volume":"30","author":"Alshaikh","year":"2019","journal-title":"Endocr Pathol"},{"issue":"4","key":"2023061601031611500_dgad098-B117","doi-asserted-by":"crossref","first-page":"E447","DOI":"10.1227\/NEU.0000000000000251","article-title":"High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series","volume":"74","author":"Zacharia","year":"2014","journal-title":"Neurosurgery"},{"issue":"3","key":"2023061601031611500_dgad098-B118","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12022-020-09647-w","article-title":"Effects of CAPTEM (capecitabine and temozolomide) on a corticotroph carcinoma and an aggressive corticotroph tumor","volume":"32","author":"Nakano-Tateno","year":"2021","journal-title":"Endocr Pathol"},{"issue":"2","key":"2023061601031611500_dgad098-B119","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11102-021-01192-x","article-title":"Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay","volume":"25","author":"Ishida","year":"2022","journal-title":"Pituitary"},{"key":"2023061601031611500_dgad098-B120","doi-asserted-by":"crossref","first-page":"916982","DOI":"10.3389\/fonc.2022.916982","article-title":"Temozolomide and capecitabine treatment for an aggressive somatotroph pituitary tumor: a case report and literature review","volume":"12","author":"Ishida","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"2023061601031611500_dgad098-B121","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1210\/jc.2018-01347","article-title":"Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab","volume":"103","author":"Lin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023061601031611500_dgad098-B122","doi-asserted-by":"crossref","first-page":"e001532","DOI":"10.1136\/jitc-2020-001532","article-title":"Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study","volume":"8","author":"Majd","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2023061601031611500_dgad098-B123","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s11102-009-0211-1","article-title":"Temozolomide (Temodar\u00ae) and capecitabine (Xeloda\u00ae) treatment of an aggressive corticotroph pituitary tumor","volume":"14","author":"Thearle","year":"2011","journal-title":"Pituitary"},{"issue":"1","key":"2023061601031611500_dgad098-B124","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13000-017-0624-5","article-title":"Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing's disease","volume":"12","author":"Joehlin-Price","year":"2017","journal-title":"Diagn Pathol"},{"issue":"4","key":"2023061601031611500_dgad098-B125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2217\/cns-2016-0011","article-title":"Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy","volume":"5","author":"Donovan","year":"2016","journal-title":"CNS Oncol"},{"issue":"12","key":"2023061601031611500_dgad098-B126","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1210\/jcem.83.12.5300","article-title":"The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors","volume":"83","author":"Kaltsas","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023061601031611500_dgad098-B127","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/A:1009975009924","article-title":"Malignant pituitary tumours","volume":"1","author":"Kaltsas","year":"1998","journal-title":"Pituitary"},{"key":"2023061601031611500_dgad098-B128","first-page":"529","article-title":"Thyrotropin-secreting pituitary carcinoma","volume":"76","author":"Mixson","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2023061601031611500_dgad098-B129","first-page":"272","article-title":"Response of silent corticotroph pituitary carcinoma to chemotherapy: case report","volume":"60","author":"He","year":"2016","journal-title":"J Neurosurg Sci"},{"issue":"1","key":"2023061601031611500_dgad098-B130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11060-017-2554-1","article-title":"Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature","volume":"135","author":"AbdelBaki","year":"2017","journal-title":"J Neurooncol"},{"issue":"7","key":"2023061601031611500_dgad098-B131","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"2023061601031611500_dgad098-B132","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.wneu.2016.09.092","article-title":"Aggressive pituitary adenomas: the dark side of the moon","volume":"97","author":"Priola","year":"2017","journal-title":"World Neurosurg"},{"issue":"5","key":"2023061601031611500_dgad098-B133","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1530\/EC-19-0065","article-title":"Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience","volume":"8","author":"Giuffrida","year":"2019","journal-title":"Endocr Connect"},{"issue":"2","key":"2023061601031611500_dgad098-B134","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3171\/2015.6.JNS15363","article-title":"Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATE: case report","volume":"125","author":"Walig\u00f3rska-Stachura","year":"2016","journal-title":"J Neurosurg"},{"issue":"1","key":"2023061601031611500_dgad098-B135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/RLU.0000000000000589","article-title":"The use of (68)Ga DOTATATE PET\/CT for diagnostic assessment and monitoring of (177)Lu DOTATATE therapy in pituitary carcinoma","volume":"40","author":"Novruzov","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"6","key":"2023061601031611500_dgad098-B136","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11102-013-0540-y","article-title":"Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: variable clinical response in preliminary evaluation","volume":"17","author":"Maclean","year":"2014","journal-title":"Pituitary"},{"issue":"3","key":"2023061601031611500_dgad098-B137","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11102-013-0494-0","article-title":"Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma","volume":"17","author":"Komor","year":"2014","journal-title":"Pituitary"},{"issue":"4","key":"2023061601031611500_dgad098-B138","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00259-019-04578-z","article-title":"An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy","volume":"47","author":"Assadi","year":"2020","journal-title":"European J Nucl Med Mol Imaging"},{"issue":"1","key":"2023061601031611500_dgad098-B139","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/eci.12010","article-title":"ACTH-secreting Crooke cell carcinoma of the pituitary","volume":"43","author":"Kov\u00e1cs","year":"2013","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"2023061601031611500_dgad098-B140","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2018-02461","article-title":"Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas","volume":"104","author":"Zhang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023061601031611500_dgad098-B141","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11102-011-0341-0","article-title":"New targeted therapies in pituitary carcinoma resistant to temozolomide","volume":"15","author":"Jouanneau","year":"2012","journal-title":"Pituitary"},{"issue":"1","key":"2023061601031611500_dgad098-B142","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1210\/en.2014-1627","article-title":"Erbb receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice","volume":"156","author":"Liu","year":"2015","journal-title":"Endocrinology"},{"issue":"2","key":"2023061601031611500_dgad098-B143","doi-asserted-by":"crossref","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","article-title":"EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas","volume":"106","author":"Cooper","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2023061601031611500_dgad098-B144","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O\u2019Kane","year":"2019","journal-title":"Br J Cancer"},{"key":"2023061601031611500_dgad098-B145","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.wneu.2018.12.174","article-title":"Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: case report and literature review","volume":"124","author":"Wang","year":"2019","journal-title":"World Neurosurg"},{"issue":"3","key":"2023061601031611500_dgad098-B146","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11102-011-0346-8","article-title":"Anti-VEGF therapy in pituitary carcinoma","volume":"15","author":"Ortiz","year":"2012","journal-title":"Pituitary"},{"issue":"15 Suppl","key":"2023061601031611500_dgad098-B147","doi-asserted-by":"crossref","first-page":"e13022","DOI":"10.1200\/jco.2013.31.15_suppl.e13022","article-title":"Metastatic ACTH-producing pituitary carcinoma managed with combination pasireotide and bevacizumab following failure of temozolamide therapy: a case report","volume":"31","author":"O\u2019Riordan","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023061601031611500_dgad098-B148","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1055\/a-1260-3975","article-title":"Bevacizumab in aggressive pituitary adenomas\u2014experience with 3 patients","volume":"129","author":"Osterhage","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6382","key":"2023061601031611500_dgad098-B149","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"2023061601031611500_dgad098-B150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2023061601031611500_dgad098-B151","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2023061601031611500_dgad098-B152","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zheng","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2023061601031611500_dgad098-B153","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1227\/neu.0000000000002024","article-title":"Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: a case report","volume":"91","author":"Shah","year":"2022","journal-title":"Neurosurgery"},{"key":"2023061601031611500_dgad098-B154","article-title":"Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy","author":"Goichot","year":"2021","journal-title":"Clin Endocrinol"},{"issue":"5","key":"2023061601031611500_dgad098-B155","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1530\/EJE-22-0647","article-title":"Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study","volume":"187","author":"Ilie","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"17","key":"2023061601031611500_dgad098-B156","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.3390\/cancers14174093","article-title":"Immunotherapy for aggressive and metastatic pituitary neuroendocrine tumors (PitNETs): state-of-the art","volume":"14","author":"Feola","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2023061601031611500_dgad098-B157","doi-asserted-by":"crossref","first-page":"576027","DOI":"10.3389\/fendo.2020.576027","article-title":"Case report: a case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy","volume":"11","author":"Lamb","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2023061601031611500_dgad098-B158","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-20-0151","article-title":"Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?","volume":"184","author":"Sol","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023061601031611500_dgad098-B159","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","article-title":"Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab","volume":"31","author":"Caccese","year":"2020","journal-title":"Anticancer Drugs"},{"issue":"14","key":"2023061601031611500_dgad098-B160","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2023061601031611500_dgad098-B161","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Gen"},{"issue":"6375","key":"2023061601031611500_dgad098-B162","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"issue":"6349","key":"2023061601031611500_dgad098-B163","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"4","key":"2023061601031611500_dgad098-B164","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"2023061601031611500_dgad098-B165","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad098\/50115881\/dgad098.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/7\/1585\/50604533\/dgad098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/7\/1585\/50604533\/dgad098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T21:21:54Z","timestamp":1701984114000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/7\/1585\/7059946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":165,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,2,28]]},"published-print":{"date-parts":[[2023,6,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad098","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,2,28]]}}}